REGENERON PHARMACEUTICALS, INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
REGENERON PHARMACEUTICALS, INC. (REGN) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $60.80 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2023-08-03
- REGENERON PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-06-30 was $5.60M.
- REGENERON PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-03-31 was $55.20M.
- REGENERON PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2022-09-30 was $116.00M.
- REGENERON PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2022-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2020 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2023-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $60.80M 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $55.20M 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $135.50M 10-Q · filed 2023-08-03 | |||
| 2022-09-30 | $116.00M 10-Q · filed 2022-11-03 | $116.00M derived: sum of 2 quarters · filed 2023-08-03 | $116.00M derived: sum of 3 quarters · filed 2023-08-03 | $116.00M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2023-08-03 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-03-31 | $0.00 10-K · filed 2023-02-06 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |